908 Devices reported Q3 revenue of $19 million, up 35%, and raised full-year 2026 guidance to $68.5 to $70 million. Device shipments exceeded 300, raising the installed base to approximately 4,400, while adjusted EBITDA loss was $1.7 million.
MASS · 908 Devices Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
The company generated nine-month continuing-operations revenue of $48.4 million versus $38.8 million, while net losses narrowed to $28.4 million from $37.7 million. Handheld product placements rose to 673 from 497, and cumulative placements reached 4,409.
908 Devices Inc. reported third-quarter revenue of $19.0 million, up 35% year-over-year, and raised full-year revenue guidance to $68.5 million to $70.0 million. It ended September 30, 2026 with $99.1 million in cash and no debt.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 11, 2026TL;DR. 908 Devices posted 23% Q2 revenue growth to $16.1M, more than halved its adjusted EBITDA loss to negative $1.9M, and raised the low end of its 2026 revenue outlook to $68-70M, while reporting an $11.9M net loss from continuing operations and pulling AVCAD out of guidance.
- + Q2 revenue grew 23% year-over-year to $16.1 million.
- + Adjusted EBITDA loss improved by more than 50% year-over-year to negative $1.9M.
- + Company raised the low end of 2026 revenue guidance to $68-70M (21-25% growth).
- + Adjusted gross margin expanded 85 basis points to 57% in Q2.
- + NearLab acquisition is ramping, with more than 35 devices sold in roughly two months post-close.
- − Net loss from continuing operations was $11.9 million in Q2 2026.
- − AVCAD program contribution was removed from 2026 core guidance, with any contribution now upside-only.
- − Recurring revenue grew only 4% year-over-year to $4.9 million.
- − Q2 cash usage of $10.2 million included $13.5M for the NearLab acquisition.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA (Non-GAAP) non-GAAP | -$4.45M | Six Months Ended June 30, 2026 | — |
| Adjusted EBITDA loss non-GAAP | 1.9M | Q2 2026 | — |
| Adjusted Gross Margin Percentage (Non-GAAP) non-GAAP | 57% | Six Months Ended June 30, 2026 | — |
| Adjusted Gross Profit (Non-GAAP) non-GAAP | $16.86M | Six Months Ended June 30, 2026 | — |
| Devices placed | 198 | Q2 2026 | — |
| Installed base | 4,101 | Q2 2026 | — |
| Product Placements - Handheld | 198 | Three Months Ended June 30, 2026 filing | — |
| Recurring revenue | 4.9M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MASS
this stock
908 Devices Inc.
|
$405.01M | +85.5% | +17.7% | — | 6.1% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
MDT
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 10, 2026
- This year
- 18
The company generated nine-month continuing-operations revenue of $48.4 million versus $38.8 million, while net losses narrowed to $28.4 million from $37.7 million. Handheld product placements rose to 673 from 497, and cumulative placements reached 4,409.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MASS | -7.8% | -13.5% | +23.0% | -13.4% | +85.5% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -10.4% | -12.3% | +22.5% | -13.2% | +74.9% |